

Appendix

Table 1: Key treatment outcomes of the targeted therapy group and the control group

	Targeted therapy group (*selpercatinib) n = 129	Control group (*pembrolizumab plus chemotherapy) n = 83
Median progression-free survival, months	24.8	11.2
Overall response rate, %	83.7	65.1
Median duration of response, months	24.2	11.5
12-month cumulative incidence rate of central nervous system (CNS) progression in patients without CNS metastases at baseline, %	1.1	14.7

*Selpercatinib is a targeted therapy drug while pembrolizumab is an immunotherapy drug.